urosphere
News & events
Urosphere will be present at the AACR annual meeting 2024
Urosphere will present a poster at the AACR congress (Tuesday Apr 9, 2024 9:00 AM - 12:30 PM in Poster section 11). Poster #4231: Decaup E. et al., A BIOBANK OF BLADDER CANCER ORGANOIDS AS A PLATFORM FOR SCREENING NEW THERAPEUTIC APPROACHES. Our team is eagerly awaiting to meet-up with you at Booth no.3645 to share how our latest services and models can help bring your research programs a step further.
BIO Digital – BIO partnering convention
June, 10-11 & 14-18, 2021 Location: Virtual
Meet2win – European Oncology Partnering Convention
May, 6- 7, 2021 Location: Virtual
Upcoming AACR Virtual Meeting II
We are pleased to announce that Urosphere will be presenting its unique Patient-Derived Xenograft (PDX) bank of prostate cancers at AACR Virtual Meeting II. Poster #1668. June 22 - 24, 2020 Virtual Meeting II Click to view our abstract and register to see the poster on June, 22nd! https://www.abstractsonline.com/pp8/#!/9045/presentation/4863
Merge of Urosphere and Urolead, creating a center of excellence in preclinical urology.
In December 2019, Urosphere acquired Urolead, a company dedicated to uro-oncology and particularly to the development of Patient-Derived Xenografts (PDX) models for kidney, bladder and prostate cancers. Urolead’s expertise and PDX Biobank strengthens Urosphere’s position by providing a full package of specifically relevant models in oncology, from cells to PDXs. "The acquisition of Urolead is an essential part of our development strategy of offering a full package of drug discovery portfolio...
Urosphere participe à la 7e édition des AFSSI Connexions les 2/3 juillet 2019 à Lyon
Urosphere sera présente sur l’espace village AFSSI les 2 et 3 juillet 2019 à Lyon. N'hésitez pas à venir nous voir sur le stand.
Urosphere/ Urolead and Institut Curie will present their last results at the AACR meeting, Denver: Bladder Cancer: Transforming the Field.
Fruit of a long term collaboration, Urosphere and its affiliate Urolead (Toulouse) and Institut Curie (Paris) will present a fully characterized biobank of PDXs from bladder cancers and its relevant use as a drug discovery platform. The results will be presented in poster session A, on Sunday, May 19th and in plenary session 5, on Monday, May 20th. Title: Establishment of a panel of patient-derived tumor xenograft models recapitulating molecular heterogeneity and drug response of...
Urosphere will be present at the European Association of Urology congress 2019.
Urosphere will present a poster at the EAU congress (from 15 to 19 March 2019). Poster 500:Patard PM et al.,Characterization of bladder organoid cultures from healthy and cancer tissues. It will be a pleasure to meet you during the EAU congress. Don't hesitate to contact us.
DMS : finalisation d’une étude préclinique sur le traitement des dysfonctions érectiles.
Voir le communiqué de presse
AACR-NIC-EORTC conference in Philadelphia, from Oct 26th to Oct 31st.
Urosphere / Urolead will be represented by Repositive’s CEO Fiona Nielsen at the AACR-NIC-EORTC conference in Philadelphia, from Oct 26th to Oct 31st. Come and meet her at booth 817.
Urosphere will be present at the AACR annual meeting 2024
Urosphere will present a poster at the AACR congress (Tuesday Apr 9, 2024 9:00 AM - 12:30 PM in Poster section 11). Poster #4231: Decaup E. et al., A BIOBANK OF BLADDER CANCER ORGANOIDS AS A PLATFORM FOR SCREENING NEW THERAPEUTIC APPROACHES. Our team is eagerly awaiting to meet-up with you at Booth no.3645 to share how our latest services and models can help bring your research programs a step further.
BIO Digital – BIO partnering convention
June, 10-11 & 14-18, 2021 Location: Virtual
Meet2win – European Oncology Partnering Convention
May, 6- 7, 2021 Location: Virtual
Upcoming AACR Virtual Meeting II
We are pleased to announce that Urosphere will be presenting its unique Patient-Derived Xenograft (PDX) bank of prostate cancers at AACR Virtual Meeting II. Poster #1668. June 22 - 24, 2020 Virtual Meeting II Click to view our abstract and register to see the poster on June, 22nd! https://www.abstractsonline.com/pp8/#!/9045/presentation/4863
Urosphere participe à la 7e édition des AFSSI Connexions les 2/3 juillet 2019 à Lyon
Urosphere sera présente sur l’espace village AFSSI les 2 et 3 juillet 2019 à Lyon. N'hésitez pas à venir nous voir sur le stand.
Urosphere/ Urolead and Institut Curie will present their last results at the AACR meeting, Denver: Bladder Cancer: Transforming the Field.
Fruit of a long term collaboration, Urosphere and its affiliate Urolead (Toulouse) and Institut Curie (Paris) will present a fully characterized biobank of PDXs from bladder cancers and its relevant use as a drug discovery platform. The results will be presented in poster session A, on Sunday, May 19th and in plenary session 5, on Monday, May 20th. Title: Establishment of a panel of patient-derived tumor xenograft models recapitulating molecular heterogeneity and drug response of...
Urosphere will be present at the European Association of Urology congress 2019.
Urosphere will present a poster at the EAU congress (from 15 to 19 March 2019). Poster 500:Patard PM et al.,Characterization of bladder organoid cultures from healthy and cancer tissues. It will be a pleasure to meet you during the EAU congress. Don't hesitate to contact us.
AACR-NIC-EORTC conference in Philadelphia, from Oct 26th to Oct 31st.
Urosphere / Urolead will be represented by Repositive’s CEO Fiona Nielsen at the AACR-NIC-EORTC conference in Philadelphia, from Oct 26th to Oct 31st. Come and meet her at booth 817.
Urosphere will be present at the International Continence Society 2017
Urosphere will present an oral communication at ICS (Florence, 12-15 september 2017)
Urosphere will be present at the European Association of Urology congress 2017
Urosphere will present two posters at the 32st annual EAU congress (24-28 March 2017).
Merge of Urosphere and Urolead, creating a center of excellence in preclinical urology.
In December 2019, Urosphere acquired Urolead, a company dedicated to uro-oncology and particularly to the development of Patient-Derived Xenografts (PDX) models for kidney, bladder and prostate cancers. Urolead’s expertise and PDX Biobank strengthens Urosphere’s position by providing a full package of specifically relevant models in oncology, from cells to PDXs. "The acquisition of Urolead is an essential part of our development strategy of offering a full package of drug discovery portfolio...
DMS : finalisation d’une étude préclinique sur le traitement des dysfonctions érectiles.
Voir le communiqué de presse
Acquisition of Urolead company.
Urosphere is pleased to announce its acquisition of Urolead company.
Urosphere presented two posters at ERA-EDTA congress
Urosphere presented two posters in collaboration with Solid Drug Development at the 53rd annual ERA-EDTA congress: Effect of JNK inhibitor in a rat model of renal ischemia-reperfusion injury (link) Effects of JNK inhibitor on puromycin aminonucleoside-induced nephropathy in rats (link) Please click on links next to the posters titles to see them.
Urosphere and Ambiotis sign a strategic collaboration agreement
Urosphere and Ambiotis another Contract Research Organization, based in Toulouse, France announce a strategic partnership to broaden and strenghten their respective activities. Under this agreement, the two companies intend to combine their skills to offer an even more integrated approach to their customers. UROSPHERE will indeed bring its expertise in building physiological and pathological animal models within the uro-genital, gastro-intestinal and oncological areas while Ambiotis will offer...
Season’s Greetings and Best Wishes!
Best wishes from UROSPHERE for a great year 2016 !
UROSPHERE ANNOUNCES ISO 9001 CERTIFICATION.
Urosphere is pleased to announce another step in its commitment to the highest quality standards. Urosphere obtained the certification of its Quality Management System (QMS) ISO 9001: 2008 provided by Lloyd's Register Quality Assurance (LRQA), a world’s leading provider of certifications. “Today, we become the first CRO specialized in preclinical pharmacology in the field of urogenital pathologies. We provide to our customers an internationally recognized certification of its QMS not only for...
ORGANOCAN : UROsphere collaborative project.
Colorectal cancers and those of the urological sphere (prostate and bladder) are among the five most common cancers. A chronic inflammatory condition predisposes to the appearance of some of these cancers (colon, prostate). Today, the available experimental models poorly simulate the biological reality and function of the body, which makes it particularly difficult to develop new drugs. The objective of the Organocan 2 project is to develop cell models in 3-dimensional (organoid) of colon,...
Season’s Greetings and Best Wishes!
Best wishes from UROsphere for a new year 2015!
Urosphere has developed new experimental models for Erectile Dysfunctions
UROsphere has recently established a scientific collaboration with Dr. Julien Allard, Founder and Chief Scientific Officer of E-Phys, an in vivo electrophysiological platform located in Clermont-Ferrand (France). Thanks to the scientific and technical expertise of Dr. Allard, an internationally reputed scientist specialized in the study of male and female sexual function, UROsphere can now offer experimental models for the assessment of drug treatment on erectile function in rats or mice: Drug...
